Gut microbione from Japanease lung cancer cohort

ABSTRACT: Gut microbiome predicts efficacy and immune-related toxicities of advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 Ab-based immunotherapy

PROVIDER: PRJEB36730 | ENA |

REPOSITORIES: ENA